Key facts
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for SynthBiome
- ·The full record, as it builds
Funding rounds
No funding rounds for SynthBiome are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SynthBiome
Provider of biotechnology research services intended to boost drug discovery. The company offers adaptive, scalable, and accurate simulations of human physiology for effective drug development, enabling research institutes to improve the efficiency of the development process.
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Founded
- 2022
- Employees
- 5
- Website
- synthbiome.com/
- Ownership
- Privately Held (backing)
SynthBiome doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SynthBiome shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SynthBiome in its N-PORT filings yet. We sweep new filings monthly.